| Published time |
Research type |
Research object |
Follow-up time |
Treatment |
Outcome |
| 2005 [17] |
Prospective cohort study |
32 North American IgAN patients with an eGFR＜60 ml/min |
2 years |
1 year of MMF, titrated up to a dose of 1000 mg bid, or placebo. All patients received RASIs medication |
29.4% in the MMF group and 13.3% in the control group reached a 50% increase in SCr (P=0.4). 17.6% in the MMF group and 13.3% in the control group had a 50% reduction in 24 h proteinuria |
| 2010 [21] |
Prospective cohort study |
207 IgAN patients with creatinine ≤ 2.0 mg/dl and proteinuria ≥ 1.0 g/d |
median follow-up of 4.9 years |
A 3-day pulse of MP in months 1, 3, and 5 in addition to both oral prednisone 0.5 mg/kg every other day and azathioprine 1.5 mg/kg per day for 6 months (n=101). steroids alone on the same schedule (n=106) |
Low-dose azathioprine to corticosteroids for 6 months does not provide additional benefit to patients with IgAN and may increase the risk for adverse events |
| 2010 [16] |
Prospective cohort study |
40 Chinese patients with IgA nephritis |
6 years |
All patients were maintained on ARB medication and half were randomized to receive MMF for 6 m |
1.5% in the MMF group and 5% in the control group reached the composite end point*. Urinary protein excretion and the albumin-to-creatinine ratio were lower with MMF treatment during the first 24 m |
| 2011 [19] |
Prospective cohort study |
22 IgAN patients with eGFR ≥ 30 ml/min, urine protein ≥ 1 g/d, BP < 130/80 mmHg |
Not known |
Methylprednisolone alone or MP combination with azathioprine for 12 months. All the patients were treated with RASIs and PFA for at least 6 m |
Two groups seem to be effective in reducing the severity of proteinuria and stabilizing renal function. |
| 2011 [22] |
Prospective cohort study |
23 IgAN patients with a GFR within 30–60 ml/min and/or proteinuria >1 g/d |
1 year |
Low-dose sirolimus plus enalapril and atorvastatin (SRL group, n=14) or enalapril plus atorvastatin (CONTROL group, n=9) |
Primary end point** improved significantly in the SRL group at 12 months. Proteinuria decreased similarly in both study groups |
| 2012 [23] |
Prospective cohort study |
14 refractory IgAN patients |
Not known |
Tacrolimus (0.05-0.1 mg/kg/d) and prednisone (0.5 mg/kg/d) for at least 6 m |
9 patients showed complete or partial remission and 7 patients achieved remission within 1 m |
* Serum creatinine doubling or end-stage renal disease.